Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 2
2017 19
2018 12
2019 7
2020 6
2021 5
2022 17
Text availability
Article attribute
Article type
Publication date

Search Results

62 results
Results by year
Filters applied: . Clear all
Page 1
The Care of the Ultra-Orthodox Jewish Patient.
Gabbay E, McCarthy MW, Fins JJ. Gabbay E, et al. Among authors: mccarthy mw. J Relig Health. 2017 Apr;56(2):545-560. doi: 10.1007/s10943-017-0356-6. J Relig Health. 2017. PMID: 28102466
At-home coronavirus testing: the next game-changer?
McCarthy MW. McCarthy MW. Expert Rev Mol Diagn. 2021 Jan;21(1):1-2. doi: 10.1080/14737159.2021.1873133. Epub 2021 Jan 11. Expert Rev Mol Diagn. 2021. PMID: 33403877 No abstract available.
Osteoarticular Mycoses.
Gamaletsou MN, Rammaert B, Brause B, Bueno MA, Dadwal SS, Henry MW, Katragkou A, Kontoyiannis DP, McCarthy MW, Miller AO, Moriyama B, Pana ZD, Petraitiene R, Petraitis V, Roilides E, Sarkis JP, Simitsopoulou M, Sipsas NV, Taj-Aldeen SJ, Zeller V, Lortholary O, Walsh TJ; International Consortium for Osteoarticular Mycoses. Gamaletsou MN, et al. Among authors: mccarthy mw. Clin Microbiol Rev. 2022 Nov 30:e0008619. doi: 10.1128/cmr.00086-19. Online ahead of print. Clin Microbiol Rev. 2022. PMID: 36448782 Review.
Teixobactin: a novel anti-infective agent.
McCarthy MW. McCarthy MW. Expert Rev Anti Infect Ther. 2019 Jan;17(1):1-3. doi: 10.1080/14787210.2019.1550357. Epub 2018 Nov 20. Expert Rev Anti Infect Ther. 2019. PMID: 30449226 No abstract available.
Cefiderocol: a novel siderophore cephalosporin.
Choi JJ, McCarthy MW. Choi JJ, et al. Among authors: mccarthy mw. Expert Opin Investig Drugs. 2018 Feb;27(2):193-197. doi: 10.1080/13543784.2018.1426745. Epub 2018 Jan 24. Expert Opin Investig Drugs. 2018. PMID: 29318906 Review.
Pharmacokinetics and Pharmacodynamics of Ibrexafungerp.
McCarthy MW. McCarthy MW. Drugs R D. 2022 Mar;22(1):9-13. doi: 10.1007/s40268-021-00376-x. Epub 2021 Dec 27. Drugs R D. 2022. PMID: 34961907 Free PMC article. Review.
Ibrexafungerp is the first drug approved in a novel antifungal class in more than two decades, and the Food and Drug Administration's decision was based on positive results from two pivotal phase III studies in which oral ibrexafungerp proved both safe and effective in pat …
Ibrexafungerp is the first drug approved in a novel antifungal class in more than two decades, and the Food and Drug Administration's
Cefiderocol to treat complicated urinary tract infection.
McCarthy MW. McCarthy MW. Drugs Today (Barc). 2020 Mar;56(3):177-184. doi: 10.1358/dot.2020.56.3.3118466. Drugs Today (Barc). 2020. PMID: 32282864 Review.
On November 14, 2019, the U.S. Food and Drug Administration (FDA) approved cefiderocol, a siderophore-cephalosporin conjugate antibiotic, for the treatment of adults with complicated urinary tract infections (cUTIs), including kidney infections caused by susceptible Gram-n …
On November 14, 2019, the U.S. Food and Drug Administration (FDA) approved cefiderocol, a siderophore-cephalosporin conjugate antibio …
62 results